Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor - sprookjes - yvandenbroek - TriplyDB

Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor

Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor

http://www.wikidata.org/entity/Q35802193

about

Chimeric antigen receptor T-cell therapy for solid tumors Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level Toward precision medicine of breast cancer Recent advances in T-cell engineering for use in immunotherapy Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies Engineered T cells for cancer treatment 5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells.A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor.Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels.Genetically engineered T cells for the treatment of cancer.Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression.Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer.Fully human CD19-specific chimeric antigen receptors for T-cell therapy.A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity.Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.Design and development of therapies using chimeric antigen receptor-expressing T cells Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside.Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma.Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma.Chimeric antigen receptor T cells: a novel therapy for solid tumors.Adoptive immunotherapy for cancer.Immune therapies for malignant mesothelioma.Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.Engineering CAR-T cells: Design concepts.Searching for targets for the systemic therapy of mesothelioma.Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells.CAR T-cell immunotherapy: The path from the by-road to the freeway?Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.Adoptive T-Cell Therapy for Solid Tumors.

P2860

Q26750908-3AC93B77-C3B8-4876-BE40-8141A1A26191 Q26752955-4DD71629-5CF1-410B-8B29-4A5D33E27ACA Q26778759-83DB68FE-8A22-4EC8-9C6D-6F8115085D82 Q27300701-CF24475B-C958-49E7-B3B8-2F33912AB778 Q28073967-8E966E46-F197-4061-8503-2EDF30EC7C62 Q28080312-54D01A77-6D54-4817-A30B-05349B36CD49 Q28395597-89474319-6774-413C-B395-06D1CB498A20 Q33578792-3AEC6C05-E815-4694-98B7-12837424DB64 Q33884816-D5846D45-C52D-4D16-AC7B-1C3846D48C1A Q34030602-8A36016B-8038-4F39-856C-757F7245F695 Q34493886-6CB00BA7-1691-4DD9-8D7D-660815D31CBD Q34645898-34DD3BB6-A6C4-46B0-A804-6F0DD092D068 Q34748489-51F12234-025F-4900-B49C-29CC97A9100E Q34893030-A4E90209-E6BF-44D2-BD5A-BA9A45546994 Q35216278-79E0C790-3F98-4052-B08F-473D8E21B2FA Q35661999-95544944-98A0-481B-AFB8-2231595A67B3 Q36132731-E3F6DD14-C9E6-4CA2-81F4-FA6E857F8AAF Q36281920-53B931AA-9AE5-45DE-A4AC-78C762541100 Q36356392-1FDFE029-D233-4F7F-ABDA-DCEE56E921AA Q36470354-26DC28EC-9627-458F-8216-2DA17F63376F Q36643661-E4DB1550-28DF-4B24-A743-C84DAC988258 Q36778126-EB2B298E-A3A3-4E03-9615-92E2DAF166DF Q36957716-540D337F-767C-4004-8E5E-AD5B0B3FE93F Q37418289-51746F70-5C43-4BC8-9D8E-87AF910F3BF3 Q37436837-EFFAF56C-66E4-4C45-B1B5-C221F9BC61F5 Q37466219-618F0873-C107-40E2-81DB-EB7C145C9A13 Q37559401-B0BF3A18-93BC-4090-8534-86DA05DC9AF7 Q37609801-229B790B-0AE0-41FC-A423-A6E42B96894A Q37619840-D88F9151-A534-401A-9F02-05B3DAC515C7 Q37621377-A85E814B-7815-41E6-BECF-7D287B8CE9B6 Q37728639-7E7019DE-F386-4441-BAA4-69BC4D49E8EB Q38170496-65CD3F18-7BAE-4A43-B006-E66567E23E20 Q38212149-9E0F80D2-370A-43A1-8E2E-74063617FBFF Q38289029-52374EDB-7EF7-426E-9C12-1C41F4F29C6C Q38290031-75CF0BDC-7358-46A7-913D-14494E65B327 Q38365768-D5101EF7-CDBE-42D2-909C-3C18CAF731A7 Q38608986-FDF1B8E9-54BB-4EF1-9B4D-2CAE3A2F99A6 Q38632105-982B51C1-402D-438B-AE8D-A94113A26599 Q38741113-4321EAF9-F46B-4569-91AD-383376D0CC0E Q38754498-FD7F0EB2-811F-4307-B611-79C2F3A59130

P2860

Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor

http://www.wikidata.org/entity/Q35802193

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Redirected antitumor activity ...... i-mesothelin chimeric receptor

@ast

Redirected antitumor activity ...... i-mesothelin chimeric receptor

@en

type

label

Redirected antitumor activity ...... i-mesothelin chimeric receptor

@ast

Redirected antitumor activity ...... i-mesothelin chimeric receptor

@en

prefLabel

Redirected antitumor activity ...... i-mesothelin chimeric receptor

@ast

Redirected antitumor activity ...... i-mesothelin chimeric receptor

@en

P1433

Q35802193-D1589795-BB92-48AC-9C20-D37CBF0B7482

P1476

Q35802193-653440E9-C2CB-4899-B1CF-ECC419C92313

P2093

Q35802193-016488FC-7B64-438F-A2F6-E7FE8ECF941D

Q35802193-3463C9C5-FC56-4F0E-B55B-040ED22C776D

Q35802193-601C02C0-437F-4002-9F7E-8669191C87B9

Q35802193-78261080-1E3F-4832-A5D5-3FCB796F1007

Q35802193-9F5A0D80-9F30-48B4-8331-8B3021C82720

Q35802193-D6E6DEBB-67DB-4867-B94E-EED602108256

Q35802193-DF3A9632-B9EE-4E9F-95D2-F9D601C5C860

P2860

Q35802193-0568EB8D-8CD6-4569-9A45-AAEEFBFE955B

Q35802193-0A852D54-11F6-47DB-8698-7B10DBEBFC0D

Q35802193-12D92E84-C9E2-41BF-8049-E4315925C603

Q35802193-18514E41-8B10-44A9-A638-9A179B6526CF

Q35802193-2893B2D1-8561-48BE-A3B7-A49DE5D40616

Q35802193-2898D7F0-91C0-4FDE-819E-0CB0ABC17041

Q35802193-3C706247-F218-438A-903A-86AB32B06DCE

Q35802193-4034E00F-ADF2-4D77-B276-97E88D30AB3E

Q35802193-44ABBC4C-6057-4082-8E0A-8C691F8A544B

Q35802193-4A159DB0-2AEA-479B-A78B-D97B48932123

P304

Q35802193-335AD696-C313-4A8D-B3F8-5BD54499887F

P31

Q35802193-61107F0F-5E98-4B40-B236-FCA41FB8FC41

P356

Q35802193-CDB91D96-DCA8-4A8C-83C7-7804EDEB0CCD

P433

Q35802193-F0EA03E2-6BBE-4D4B-9246-8E01CFA9DA2B

P478

Q35802193-CC81922B-7743-4124-B599-B2E37405220E

P577

Q35802193-5F81949A-6DB9-4ABA-AD51-B6B602DF9044

P5875

Q35802193-ADB470B8-7D55-4E1C-96F2-91AC5A24F945

P698

Q35802193-1C5AE876-A357-4884-8D9B-9E47F47ACAEE

P932

Q35802193-8DC21CE1-8E3F-4BF4-8507-C90BC0011FC8

P356

P1433

Molecular Therapy

P1476

Redirected antitumor activity ...... i-mesothelin chimeric receptor

@en

P2093

Daniel J Powell

http://www.w3.org/2001/XMLSchema#string

Evripidis Lanitis

http://www.w3.org/2001/XMLSchema#string

George Coukos

http://www.w3.org/2001/XMLSchema#string

Ian S Hagemann

http://www.w3.org/2001/XMLSchema#string

Mathilde Poussin

http://www.w3.org/2001/XMLSchema#string

Nathalie Scholler

http://www.w3.org/2001/XMLSchema#string

Raphael Sandaltzopoulos

http://www.w3.org/2001/XMLSchema#string

P2860

Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma

A binding domain on mesothelin for CA125/MUC16

Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma

Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer

Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).

Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library.

Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity.

Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.

P304

633-643

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2011.256

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51839829

http://www.w3.org/2001/XMLSchema#string

P698

22127019

http://www.w3.org/2001/XMLSchema#string

P932

3293635

http://www.w3.org/2001/XMLSchema#string